Biomendex is a Finnish biotechnology startup founded in 2018, specializing in the development and manufacturing of adaptable synthetic bone substitute materials for bone regeneration. Their innovative product, Adaptos®, represents the first bioactive bone graft substitute that surgeons can customize to fit the patient's needs, mimicking bone by being resilient and bioactive. The company's mission is to revolutionize the treatment of bone voids by delivering versatile and improved medical devices to operating theaters, ultimately enhancing surgical outcomes and minimizing operational risks in bone regeneration. With a focus on Biotechnology, Health Care, and Manufacturing, Biomendex aims to provide the freedom to operate by leveraging cutting-edge technology in the field of bone regeneration. Currently, no specific information is available regarding the company's last investment and the parties involved.
There is no investment information
No recent news or press coverage available for Biomendex.